Campbell Newman Asset Management Inc. Sells 3,292 Shares of Johnson & Johnson (NYSE:JNJ)

Campbell Newman Asset Management Inc. decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 12.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 22,601 shares of the company's stock after selling 3,292 shares during the quarter. Campbell Newman Asset Management Inc.'s holdings in Johnson & Johnson were worth $3,748,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in JNJ. Tallon Kerry Patrick bought a new stake in Johnson & Johnson during the 4th quarter worth about $290,000. Capital & Planning LLC grew its holdings in Johnson & Johnson by 13.6% during the 4th quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock worth $221,000 after acquiring an additional 183 shares during the last quarter. Brighton Jones LLC grew its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the last quarter. Union Bancaire Privee UBP SA bought a new stake in Johnson & Johnson during the 4th quarter worth about $85,886,000. Finally, Peterson Wealth Services lifted its position in Johnson & Johnson by 5.4% during the 4th quarter. Peterson Wealth Services now owns 13,111 shares of the company's stock valued at $1,896,000 after purchasing an additional 669 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Up 0.2%

Shares of JNJ traded up $0.24 during mid-day trading on Friday, hitting $156.90. 6,587,488 shares of the company's stock were exchanged, compared to its average volume of 7,963,253. The company has a market cap of $377.52 billion, a PE ratio of 23.59, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a 50-day simple moving average of $153.84 and a 200 day simple moving average of $153.71. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on JNJ shares. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Royal Bank of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 16th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their target price for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.